Ireland-based Vivasure Medical said today it launched its PerQseal closure device intended for large-bore transcatheter procedures.
The newly launched device is intended for novel transcatheter endovascular procedures including transcatheter aortic valve replacements, thoracic endovascular aneurysm repairs and endovascular abdominal aneurysm repairs, which require large-bore femoral artery access. The system consists of an intravascular patch to seal the vessel from the inside.
Vivasure Medical touted the PerQseal as the first sutureless, fully absorbable synthetic implant for large bore arterial punctures.
“Closing the artery has been a concern since we started using transcatheter techniques for valve implantation. The PerQseal device is a very innovative solution for closing large holes, and we are enthusiastic to make it part of our armamentarium,” Horst Sievert of Frankfurt, Germany’s CardioVascular Center said in a prepared statement.
“We’re excited that the PerQseal device is now widely available to European physicians, providing a safe and simple option for the closure of large puncture holes that leaves behind no sutures, metal implants, or collagen. This commercial launch is a key milestone for Vivasure as we journey to enable better patient outcomes in fully percutaneous large-bore endovascular procedures,” VivaSure Medical co-founder & CEO Gerard Brett said in a prepared release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.